MetaCap

Cellectis S.A. (CLLS) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed Cellectis S.A. (CLLS) over the past year, gaining 3.0% versus a loss of 80.4%. Over five years, CLLS leads with a -89.4% price change compared with -92.5% for PDSB. PDS Biotechnology is the larger company by market cap ($95.4 million vs $92.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLLS-80.36%PDSB+2.97%
+122%+16%-90%
Nov 21, 20251 yearNov 20, 2026
CLLS-89.66%PDSB-92.26%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLLS versus PDSB key metrics
MetricCLLSPDSB
Share price$0.9209$0.7774
Market cap$92.76M$95.39M
1-day change-7.89%-3.70%
YTD return-80.97%+0.96%
1-year return-80.36%+2.97%
5-year return-89.40%-92.46%
EPS (TTM)$-1.26$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.95M—
Revenue growth (YoY)+75.76%—
Net income (latest FY)$-67.59M$-34.50M
Gross margin100.00%—
Operating margin-45.34%—
Net margin-92.66%—
52-week high$5.45$1.79
52-week low$0.881$0.195
Distance from 52-week high-83.10%-56.57%
Analyst consensusbuystrong_buy
Avg. price target upside+497.24%+478.85%
Average volume115.00K25.64M
Shares outstanding72.73M122.70M
Employees22421
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed CLLS by 83.3 percentage points over the past year.

About Cellectis S.A.

CLLS stock →

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).

Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

CLLS vs PDSB FAQ

Which is bigger, Cellectis S.A. or PDS Biotechnology?

PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $92.76M for Cellectis S.A. (CLLS).

Which stock has performed better over the past year, CLLS or PDSB?

PDSB returned +2.97% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.

Are Cellectis S.A. and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons